Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of Macitentan in Healthy Japanese Males
NCT04500808Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of macitentan in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Adverse Events of Special Interest and 5 more. Started Jul 2020; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04500808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500808.